Tag Archive for: CBO

Nucleome Therapeutics appoints Bhavna Hunjan as Chief Business Officer

Oxford, UK, 27 May 2025 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company harnessing the power of non-coding human genetics to discover first-in-class antibody treatments for inflammatory diseases, announces it has appointed Bhavna Hunjan as Chief Business Officer with immediate effect. Read more…

Chief Business Officers: Shedding Light on Biotech’s Dealmakers 

Stephanie Bewick, Chief Business Officer at Destiny Pharma outlines her experiences of how a CBO maximises their company’s commercial appeal and lands deals in the biotech industry…